Summaries for patients. The cost-effectiveness of full Medicare coverage of angiotensin-converting enzyme inhibitors for patients with diabetes.
D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000191:economics* / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000517:prevention & control*; D003362:Cost-Benefit Analysis; D003922:Diabetes Mellitus, Type 1 / Q000150:complications; D003924:Diabetes Mellitus, Type 2 / Q000150:complications; D003925:Diabetic Angiopathies / Q000517:prevention & control*; D003928:Diabetic Nephropathies / Q000517:prevention & control*; D016527:Drug Costs; D006801:Humans; D008390:Markov Chains; D006278:Medicare / Q000191:economics*; D012680:Sensitivity and Specificity; D014481:United States
D000806:Angiotensin-Converting Enzyme Inhibitors